Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)
Abstract:Background: rVWF (vonicog alfa; Vonvendi ®,Baxalta US Inc, a Takeda company, Lexington, MA, USA) is a purified recombinant VWF concentrate approved for on-demand (OD) treatment of hemorrhage and management of surgical bleeding in adults with VWD. The efficacy and safety of rVWF prophylaxis has also been evaluated in a recent open-label phase 3 trial in adults with severe VWD (NCT02973087).
Aims: To evaluate the exposure-response (ER) relationship between VWF activity (measured by VWF:ristocetin … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.